Product Description
TAK-816 is a conjugated Hib vaccine being tested in healthy infants aged 3-6 months at the time of the first dose. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01379846)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Subcutaneous, Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Influenza, Human|Haemophilus Infections|Myelitis|Diphtheria|Cellulitis|Sepsis|Arthritis, Infectious|Epiglottitis|Pneumonia|Tetanus|Meningitis, Haemophilus
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| JapicCTI-142454 | P3 |
Completed |
Influenza, Human|Haemophilus Infections |
2015-09-30 |
|||
| TAK-816/OCT-002 | P3 |
Completed |
Influenza, Human |
2015-03-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
| JapicCTI-111516 | P3 |
Completed |
Influenza, Human |
2013-07-31 |
|||
| TAK-816/CCT-001 | P3 |
Completed |
Tetanus|Pneumonia|Epiglottitis|Influenza, Human|Cellulitis|Meningitis, Haemophilus|Arthritis, Infectious|Sepsis|Myelitis|Diphtheria |
2013-02-01 |
2024-06-06 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|